NET AVENGERS
A team approach to fighting an often overlooked cancer
Cameron London will never forget the moment it all changed. The family was opening presents Christmas morning 2024 when things started getting really bad.
“My stomach hadn’t felt good all morning,” London recalls, “but by the time we were done playing Santa Claus, I was in real active pain. I had to excuse myself, and see if I could manage this.”
She couldn’t. The pain just got worse.
“It was horrible, and by the time we drove to the emergency room, I was vomiting significantly,” London says. A CT scan revealed she had colitis, but doctors suspected her symptoms were more likely caused by food poisoning or a stomach bug.
Later, doctors would determine it was none of those things. The CT scan didn’t detect the neuroendocrine cancer that was growing inside of her and making her sick. But then, that’s one of the problems with neuroendocrine tumors, or NETs, sometimes called silent cancers — they’re hard to find. They tend to grow slowly and often show no early signs. But when they do, the symptoms can be vague and non-specific — like stomach pain — and mimic common, less serious conditions.
“Those tumors can often get missed on imaging over the course of several years,” says Daniel Halperin, a medical oncologist at Winship Cancer Institute of Emory University, associate professor and vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. “We’ll meet patients and go back over their old scans and realize it was there years earlier — it just wasn’t recognized.”
Daniel Halperin
Daniel Halperin
In London’s case, the road to discovery began with a trip to the ER and follow-up with her primary care physician, who initially thought her symptoms were caused by gallbladder or digestive trouble. A subsequent HIDA (hepatobiliary iminodiacetic acid) scan showed that her gallbladder wasn’t the problem. It took a colonoscopy in March 2025 to finally reveal what was going on.
“When the GI doctor told me it was probably cancer, I immediately thought, ‘colon cancer,’” says London. She learned a few days later it was something she’d never heard of — neuroendocrine cancer.
Most cancers are defined by the organ where they originate — lung cancer in the lungs, colon cancer in the colon, and so on.
NETs come from neuroendocrine cells, which act as messengers between the nervous (“neuro”) system and the hormone-producing endocrine system. They receive signals from the brain and release hormones that regulate functions such as metabolism and digestion. Here’s the tricky part: because neuroendocrine cells are scattered throughout the body, NETs can develop in many different organs, including the lungs, pancreas, small intestine and rectum.
In other words, NETs have plenty of places to hide.
Mainly, when London heard “cancer,” she wondered what it could mean for her and her family — she and husband Jeremy have two daughters, ages two and five.
“After the diagnosis, I was not the upbeat, ‘I’m gonna beat this’ stereotype — my head went to dark places,” she says. “We had really tried to make a family — I had my kids at 37 and 40, and the hardest part about all of this was the notion that I might not be around to watch them grow up.”
Cameron London
Cameron London
Cameron London will never forget the moment it all changed. The family was opening presents Christmas morning 2024 when things started getting really bad.
“My stomach hadn’t felt good all morning,” London recalls, “but by the time we were done playing Santa Claus, I was in real active pain. I had to excuse myself, and see if I could manage this.”
She couldn’t. The pain just got worse.
“It was horrible, and by the time we drove to the emergency room, I was vomiting significantly,” London says. A CT scan revealed she had colitis, but doctors suspected her symptoms were more likely caused by food poisoning or a stomach bug.
Later, doctors would determine it was none of those things. The CT scan didn’t detect the neuroendocrine cancer that was growing inside of her and making her sick. But then, that’s one of the problems with neuroendocrine tumors, or NETs, sometimes called silent cancers — they’re hard to find. They tend to grow slowly and often show no early signs. But when they do, the symptoms can be vague and non-specific — like stomach pain — and mimic common, less serious conditions.
“Those tumors can often get missed on imaging over the course of several years,” says Daniel Halperin, a medical oncologist at Winship Cancer Institute of Emory University, associate professor and vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. “We’ll meet patients and go back over their old scans and realize it was there years earlier — it just wasn’t recognized.”
Daniel Halperin
Daniel Halperin
In London’s case, the road to discovery began with a trip to the ER and follow-up with her primary care physician, who initially thought her symptoms were caused by gallbladder or digestive trouble. A subsequent HIDA (hepatobiliary iminodiacetic acid) scan showed that her gallbladder wasn’t the problem. It took a colonoscopy in March 2025 to finally reveal what was going on.
“When the GI doctor told me it was probably cancer, I immediately thought, ‘colon cancer,’” says London. She learned a few days later it was something she’d never heard of — neuroendocrine cancer.
Most cancers are defined by the organ where they originate — lung cancer in the lungs, colon cancer in the colon, and so on.
NETs come from neuroendocrine cells, which act as messengers between the nervous (“neuro”) system and the hormone-producing endocrine system. They receive signals from the brain and release hormones that regulate functions such as metabolism and digestion. Here’s the tricky part: because neuroendocrine cells are scattered throughout the body, NETs can develop in many different organs, including the lungs, pancreas, small intestine and rectum.
In other words, NETs have plenty of places to hide.
Mainly, when London heard “cancer,” she wondered what it could mean for her and her family — she and husband Jeremy have two daughters, ages two and five.
“After the diagnosis, I was not the upbeat, ‘I’m gonna beat this’ stereotype — my head went to dark places,” she says. “We had really tried to make a family — I had my kids at 37 and 40, and the hardest part about all of this was the notion that I might not be around to watch them grow up.”
Avengers, assemble!
Halperin might be likened to the Marvel comics hero Nick Fury where it comes to The Avengers: a team leader surrounded by talented, hyper-focused clinicians with distinct specialties — or superpowers, if you like.
And just in the nick of time, too, because NETs are turning up in strikingly greater numbers, wreaking super villain havoc. In the past 40 years, diagnoses have increased more than fivefold and more than 28,000 people in the U.S. are diagnosed with neuroendocrine cancer each year.
Udhayvir Grewal
Udhayvir Grewal
“We’re definitely seeing a lot more neuroendocrine tumor patients now,” says Udhayvir Grewal, a medical oncologist who is part of Winship’s NET team, “and we still do not fully understand the exact drivers for the rising incidence. What we know for sure is that the incidence is rising at least partly because we have better imaging technologies, and therefore we’ve gotten a lot better at detection overall.” An assistant professor in the Department of Hematology and Medical Oncology in the Emory School of Medicine, Grewal joined the Winship clinical staff in 2025, following a fellowship at the University of Iowa Holden Comprehensive Cancer Center, long considered a leading hub for NET research and care.
Po Hien Ear
Po Hien Ear
The Iowa program trained a generation of NET specialists and researchers, like Grewal and the Winship team’s newest addition, Po Hien Ear, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
“When both of them joined our existing team, the consensus was that we’re the Avengers alright,” Halperin says. “What’s incredible about it to me is that these are some of the best people in the country and we didn’t go out and recruit them — they came to us. They found out what Winship was creating and reached out. The message was, ‘I see what you are building and I want to be part of it.”
The different specialists who make up the multidisciplinary team are increasing. Meanwhile the team members are attending to at least one minor organizational task — “We’re kind of fighting over which character we are right now,” says Ear, who joined the team in February 2026, adding with a chuckle, “I think Dr. Halperin hopes I’ll be Black Widow but I prefer Captain Marvel, or possibly Iron Woman.”
Halperin might be likened to the Marvel comics hero Nick Fury where it comes to The Avengers: a team leader surrounded by talented, hyper-focused clinicians with distinct specialties — or superpowers, if you like.
And just in the nick of time, too, because NETs are turning up in strikingly greater numbers, wreaking super villain havoc. In the past 40 years, diagnoses have increased more than fivefold and more than 28,000 people in the U.S. are diagnosed with neuroendocrine cancer each year.
Udhayvir Grewal
Udhayvir Grewal
“We’re definitely seeing a lot more neuroendocrine tumor patients now,” says Udhayvir Grewal, a medical oncologist who is part of Winship’s NET team, “and we still do not fully understand the exact drivers for the rising incidence. What we know for sure is that the incidence is rising at least partly because we have better imaging technologies, and therefore we’ve gotten a lot better at detection overall.” An assistant professor in the Department of Hematology and Medical Oncology in the Emory School of Medicine, Grewal joined the Winship clinical staff in 2025, following a fellowship at the University of Iowa Holden Comprehensive Cancer Center, long considered a leading hub for NET research and care.
Po Hien Ear
Po Hien Ear
The Iowa program trained a generation of NET specialists and researchers, like Grewal and the Winship team’s newest addition, Po Hien Ear, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
“When both of them joined our existing team, the consensus was that we’re the Avengers alright,” Halperin says. “What’s incredible about it to me is that these are some of the best people in the country and we didn’t go out and recruit them — they came to us. They found out what Winship was creating and reached out. The message was, ‘I see what you are building and I want to be part of it.”
The different specialists who make up the multidisciplinary team are increasing. Meanwhile the team members are attending to at least one minor organizational task — “We’re kind of fighting over which character we are right now,” says Ear, who joined the team in February 2026, adding with a chuckle, “I think Dr. Halperin hopes I’ll be Black Widow but I prefer Captain Marvel, or possibly Iron Woman.”
The GLP-1 connection
Whatever costume she wears, Ear already is making an impact in the fight against NETs. Her lab builds better models of the disease, growing 3D patient-derived organoids — “little organs on a chip,” she says — from tumors that patients donate after surgery.
Researchers historically lacked reliable NET lab models, which made it tough to predict which treatments might work best. Now they can extract tumor cells and surrounding cells from the donated samples, and create organoids, “which allows us to test a drug and see if it slows tumor growth, or triggers cell death or alters hormone secretion, so that we can develop better treatments,” says Ear, who adds that these mini-tumors allow researchers to screen multiple therapies in just a few weeks.
That’s especially important now, she says, in an era of wildly popular GLP-1 drugs like semaglutide. For millions of people with diabetes and/or obesity, GLP-1 drugs are game-changers because they help control blood sugar, curb appetite and promote weight loss in a way that other treatments never could before.
But research suggests that GLP-1 drugs may also turbocharge certain neuroendocrine tumors. The GLP-1 receptor was first cloned from an NET sample, and some NETs are packed with GLP-1 receptors — the very targets that drugs like semaglutide latch onto. And that’s what worries Ear: when a GLP-1 drug hits those tumors, it may act like fuel instead of medicine.
“These cancer cells can be covered in GLP‑1 receptors,” she explains. “When the drug binds, it sends a powerful signal that can tell the cells to grow and to pump out more hormones — exactly what we don’t want in this kind of cancer.”
Previous research using rodent models have earned semaglutide (Ozempic, Wegovy, Rybelsus) an FDA black-box warning for certain thyroid NETs because they bind to GLP-1 receptors which are present in some neuroendocrine tissues. Fortunately, no human thyroid NETs have the GLP-1 receptor according to the latest findings. However, 7% of neuroendocrine cancers have the receptors and would require further testing. Now, with the new organoids and better human NET models in hand, Ear and her collaborators can expose real human tissue to GLP-1 drugs and see what happens in real time.
“We’ve made a lot of progress developing these human models of NETs, and that’s really powerful for patients,” Ear says.
Whatever costume she wears, Ear already is making an impact in the fight against NETs. Her lab builds better models of the disease, growing 3D patient-derived organoids — “little organs on a chip,” she says — from tumors that patients donate after surgery.
Researchers historically lacked reliable NET lab models, which made it tough to predict which treatments might work best. Now they can extract tumor cells and surrounding cells from the donated samples, and create organoids, “which allows us to test a drug and see if it slows tumor growth, or triggers cell death or alters hormone secretion, so that we can develop better treatments,” says Ear, who adds that these mini-tumors allow researchers to screen multiple therapies in just a few weeks.
That’s especially important now, she says, in an era of wildly popular GLP-1 drugs like semaglutide. For millions of people with diabetes and/or obesity, GLP-1 drugs are game-changers because they help control blood sugar, curb appetite and promote weight loss in a way that other treatments never could before.
But research suggests that GLP-1 drugs may also turbocharge certain neuroendocrine tumors. The GLP-1 receptor was first cloned from an NET sample, and some NETs are packed with GLP-1 receptors — the very targets that drugs like semaglutide latch onto. And that’s what worries Ear: when a GLP-1 drug hits those tumors, it may act like fuel instead of medicine.
“These cancer cells can be covered in GLP‑1 receptors,” she explains. “When the drug binds, it sends a powerful signal that can tell the cells to grow and to pump out more hormones — exactly what we don’t want in this kind of cancer.”
Previous research using rodent models have earned semaglutide (Ozempic, Wegovy, Rybelsus) an FDA black-box warning for certain thyroid NETs because they bind to GLP-1 receptors which are present in some neuroendocrine tissues. Fortunately, no human thyroid NETs have the GLP-1 receptor according to the latest findings. However, 7% of neuroendocrine cancers have the receptors and would require further testing. Now, with the new organoids and better human NET models in hand, Ear and her collaborators can expose real human tissue to GLP-1 drugs and see what happens in real time.
“We’ve made a lot of progress developing these human models of NETs, and that’s really powerful for patients,” Ear says.
Treatment plans
Halperin guides the overall NET program and is responsible for building the multidisciplinary team, while surgical oncologist Seth Concors leads the Emory-Winship NET clinic, a job he likens to orchestrating a complex mission. Surgery is one piece of a large puzzle.
“Surgery is often the most critical part of a patient’s care,” says Concors, assistant professor at Emory University School of Medicine. He stresses the challenge of operating on tumors that are often seen at Stage 4. “These can be technically complex, six- to eight-hour operations,” he says. “But the multidisciplinary management is just as important as a potentially curative surgical procedure. And each of our experts contributes a unique perspective to ensure patients receive the right therapy at the right time.”
Seth Concors
Seth Concors
From demanding liver and small bowel procedures near major blood vessels, to planning clinical trial participation, Concors navigates treatment plans that can extend lives by decades.
And when it comes to mapping out a personalized treatment plan, “there is no one right answer,” says Grewal. “But there’s always personalized decision-making that goes into each patient’s case.”
NETs often spread to the liver, and options range from surgery to systemic therapy, liver-directed procedures or radiation. Timing is always crucial. Grewal stresses early detection, as difficult as that can be. “What really bothers me about delays in diagnosis,” he says, “is that almost always, patients have had symptoms for months or years, but the actual causes were overlooked and nobody’s paid attention.”
Halperin guides the overall NET program and is responsible for building the multidisciplinary team, while surgical oncologist Seth Concors leads the Emory-Winship NET clinic, a job he likens to orchestrating a complex mission. Surgery is one piece of a large puzzle.
“Surgery is often the most critical part of a patient’s care,” says Concors, assistant professor at Emory University School of Medicine. He stresses the challenge of operating on tumors that are often seen at Stage 4. “These can be technically complex, six- to eight-hour operations,” he says. “But the multidisciplinary management is just as important as a potentially curative surgical procedure. And each of our experts contributes a unique perspective to ensure patients receive the right therapy at the right time.”
Seth Concors
Seth Concors
From demanding liver and small bowel procedures near major blood vessels, to planning clinical trial participation, Concors navigates treatment plans that can extend lives by decades.
And when it comes to mapping out a personalized treatment plan, “there is no one right answer,” says Grewal. “But there’s always personalized decision-making that goes into each patient’s case.”
NETs often spread to the liver, and options range from surgery to systemic therapy, liver-directed procedures or radiation. Timing is always crucial. Grewal stresses early detection, as difficult as that can be. “What really bothers me about delays in diagnosis,” he says, “is that almost always, patients have had symptoms for months or years, but the actual causes were overlooked and nobody’s paid attention.”
NETs on trial
Many of Halperin’s patients arrive after years of puzzling symptoms. Some were treated for irritable bowel syndrome or another condition before imaging or a biopsy finally revealed a NET. For Halperin, that complexity is a big reason he does what he does.
“There’s just not a lot of high-quality information about NETs out there,” Halperin says. He credits mentorship for steering him into the field. Early in his career, a senior physician encouraged him to consider focusing on NETs “because there weren’t enough folks doing this kind of work. He told me that anyone who was invested could really help a lot of patients. That appealed to me.”
The concept of bringing others into the field has guided Halperin for 20 years, and at Winship he’s built a NET program that includes surgeons, pathologists, interventional radiologists, nuclear medicine specialists and other experts who evaluate each case together.
The team reviews scans and pathology, weighing options such as surgery or other procedures and therapies, depending on the patient and the disease. Clinical trials are also a critical consideration for the Winship NET team in how it approaches patient care. For Halperin, this kind of research is a necessity in a field where standard therapies are limited.
“I am a clinical trialist, and I make no bones about it,” Halperin says. “My bias is that standard of care is just not good enough, and we must do something new and different.”
Consequently, clinical research opportunities are considered early. When a new NET patient comes to Winship, the multidisciplinary team reviews each case together, discussing all the options, including whether a patient might benefit from one of Winship’s ongoing clinical trials.
“Everyone at the table makes sure that every single patient is considered for our entire portfolio of clinical trials every single time,” says Concors.
One study is testing whether a particular therapy should be used earlier in a patient’s treatment plan, rather than as a last resort, which often has been the case. Other studies are evaluating next generation radioligand drugs designed for greater potency over a longer period.
Meanwhile, researchers are testing new targeted therapies that deliver cancer-killing agents directly to tumor cells without radiation. Winship also is participating in a Phase 1 trial of a CAR T-cell therapy engineered specifically to recognize and attack NETs — an approach available at only a handful of clinics worldwide.
“Clinical research is one of those areas where patients and investigators partner to make a difference,” Halperin says. “Patients get the options they have today because someone else volunteered for a trial. And when you tell a patient afterward that their participation helped change the standard of care — that they helped us learn something we didn’t know before and that patients who come after them will benefit — that’s really special.”
Many of Halperin’s patients arrive after years of puzzling symptoms. Some were treated for irritable bowel syndrome or another condition before imaging or a biopsy finally revealed a NET. For Halperin, that complexity is a big reason he does what he does.
“There’s just not a lot of high-quality information about NETs out there,” Halperin says. He credits mentorship for steering him into the field. Early in his career, a senior physician encouraged him to consider focusing on NETs “because there weren’t enough folks doing this kind of work. He told me that anyone who was invested could really help a lot of patients. That appealed to me.”
The concept of bringing others into the field has guided Halperin for 20 years, and at Winship he’s built a NET program that includes surgeons, pathologists, interventional radiologists, nuclear medicine specialists and other experts who evaluate each case together.
The team reviews scans and pathology, weighing options such as surgery or other procedures and therapies, depending on the patient and the disease. Clinical trials are also a critical consideration for the Winship NET team in how it approaches patient care. For Halperin, this kind of research is a necessity in a field where standard therapies are limited.
“I am a clinical trialist, and I make no bones about it,” Halperin says. “My bias is that standard of care is just not good enough, and we must do something new and different.”
Consequently, clinical research opportunities are considered early. When a new NET patient comes to Winship, the multidisciplinary team reviews each case together, discussing all the options, including whether a patient might benefit from one of Winship’s ongoing clinical trials.
“Everyone at the table makes sure that every single patient is considered for our entire portfolio of clinical trials every single time,” says Concors.
One study is testing whether a particular therapy should be used earlier in a patient’s treatment plan, rather than as a last resort, which often has been the case. Other studies are evaluating next generation radioligand drugs designed for greater potency over a longer period.
Meanwhile, researchers are testing new targeted therapies that deliver cancer-killing agents directly to tumor cells without radiation. Winship also is participating in a Phase 1 trial of a CAR T-cell therapy engineered specifically to recognize and attack NETs — an approach available at only a handful of clinics worldwide.
“Clinical research is one of those areas where patients and investigators partner to make a difference,” Halperin says. “Patients get the options they have today because someone else volunteered for a trial. And when you tell a patient afterward that their participation helped change the standard of care — that they helped us learn something we didn’t know before and that patients who come after them will benefit — that’s really special.”
Seeing is believing, and treating
For patients with NETs, and the doctors who treat them, seeing truly is believing. Once a tumor is confirmed, imaging maps its exact location, providing a sense of clarity that guides treatment and setting the stage for treatments targeted with pinpoint accuracy, like radioligand therapies.
Some of Winship’s clinical research is focused on expanding this approach, which delivers radiation directly to tumor cells. The treatment uses specially engineered molecules that seek out cancer cells and irradiate them wherever they appear. Halperin calls it one of the most significant advances of the past decade.
Samia Muzahir
Samia Muzahir
“We see what we treat, or we treat what we see,” says Samia Muzahir, a nuclear medicine physician on the NET team who specializes in theranostics — as the name implies, a combination of therapy and diagnostics.
In theranostics, doctors use PET/CT scans to detect a specific molecule, or marker, present on NET cells, identifying exactly where tumors are in the body. Once found, the same marker guides treatment: a radioligand — Muzahir has been working with lutetium-177 dotatate — attaches to the marker and delivers radiation directly to the cancer cells.
So basically, theranostics is like a GPS for cancer treatment. Imaging also drives minimally invasive approaches to NET treatment.
Meghan Lilly
Meghan Lilly
Another member of the NET Avengers, interventional radiologist Meghan Lilly, uses scans to guide tissue sampling, confirm diagnoses and treat tumors in the liver with techniques like thermal ablation or cryoablation.
“Patients with neuroendocrine cancer can live for many years and will potentially require multiple treatments,” Lilly says, adding that the increased use of nuclear-medicine based radiation therapy demands careful, coordinated planning, to ensure these procedures are timed thoughtfully, maximizing benefit while minimizing unnecessary interventions.
For patients with NETs, and the doctors who treat them, seeing truly is believing. Once a tumor is confirmed, imaging maps its exact location, providing a sense of clarity that guides treatment and setting the stage for treatments targeted with pinpoint accuracy, like radioligand therapies.
Some of Winship’s clinical research is focused on expanding this approach, which delivers radiation directly to tumor cells. The treatment uses specially engineered molecules that seek out cancer cells and irradiate them wherever they appear. Halperin calls it one of the most significant advances of the past decade.
Samia Muzahir
Samia Muzahir
“We see what we treat, or we treat what we see,” says Samia Muzahir, a nuclear medicine physician on the NET team who specializes in theranostics — as the name implies, a combination of therapy and diagnostics.
In theranostics, doctors use PET/CT scans to detect a specific molecule, or marker, present on NET cells, identifying exactly where tumors are in the body. Once found, the same marker guides treatment: a radioligand — Muzahir has been working with lutetium-177 dotatate — attaches to the marker and delivers radiation directly to the cancer cells.
So basically, theranostics is like a GPS for cancer treatment. Imaging also drives minimally invasive approaches to NET treatment.
Meghan Lilly
Meghan Lilly
Another member of the NET Avengers, interventional radiologist Meghan Lilly, uses scans to guide tissue sampling, confirm diagnoses and treat tumors in the liver with techniques like thermal ablation or cryoablation.
“Patients with neuroendocrine cancer can live for many years and will potentially require multiple treatments,” Lilly says, adding that the increased use of nuclear-medicine based radiation therapy demands careful, coordinated planning, to ensure these procedures are timed thoughtfully, maximizing benefit while minimizing unnecessary interventions.
Two surgeries, one journey
After Cameron London found out what kind of cancer she had, a Google search for “NET specialists in Atlanta” led her to Halperin’s office. Her initial appointment lasted four hours and she met everyone on her care team — physicians, nurses, nutritionists.
“I quickly felt like there was this amazing team on my side, they were on top of it and things were moving forward,” London says. “That gave me confidence when I needed it.”
And she needed plenty of it for the road ahead.
The plan from that first whirlwind day with the NET Avengers was straightforward: remove the digestive tract tumor, ablate nodes on her liver, remove her gallbladder, then monitor her closely. Surgery was planned for May, five months after she first felt those stomach pains on Christmas morning.
But then, the PET scan revealed something else. Follow-up imaging and a biopsy confirmed another grade-1 NET in her right breast. There was discussion of doing everything at once, the breast tumor and the digestive tract. But Winship surgical oncologist Monica Rizzo, who specializes in breast cancer, advocated for two separate procedures — for London’s safety and comfort.
“And I’m so glad we did it that way,” London says. “It would have been very uncomfortable to go through all of that at once.”
So, Concors performed the digestive tract surgery in June 2024 and Rizzo performed the lumpectomy a month later.
“Right now, it’s just monitoring,” London says. She has had two CT scans that have shown no evidence of disease, which means regular imaging and checkups going forward — and life with a husband and two girls who were always on her mind throughout the ordeal.
“I remember going down that dark road, and I know those feelings are normal,” she says. “But it’s also important to surround yourself with the right team, and to know that it can be OK — you can be OK, but you’ll go through a lot of stuff. Yes, there is a before and an after. But that doesn’t mean you can’t live a very happy and fulfilled life.”
Jerry Grillo is a veteran journalist and two-time Georgia Author of the Year nominee.
Designed by Linda Dobson
Photography by Jenni Girtman
After Cameron London found out what kind of cancer she had, a Google search for “NET specialists in Atlanta” led her to Halperin’s office. Her initial appointment lasted four hours and she met everyone on her care team — physicians, nurses, nutritionists.
“I quickly felt like there was this amazing team on my side, they were on top of it and things were moving forward,” London says. “That gave me confidence when I needed it.”
And she needed plenty of it for the road ahead.
The plan from that first whirlwind day with the NET Avengers was straightforward: remove the digestive tract tumor, ablate nodes on her liver, remove her gallbladder, then monitor her closely. Surgery was planned for May, five months after she first felt those stomach pains on Christmas morning.
But then, the PET scan revealed something else. Follow-up imaging and a biopsy confirmed another grade-1 NET in her right breast. There was discussion of doing everything at once, the breast tumor and the digestive tract. But Winship surgical oncologist Monica Rizzo, who specializes in breast cancer, advocated for two separate procedures — for London’s safety and comfort.
“And I’m so glad we did it that way,” London says. “It would have been very uncomfortable to go through all of that at once.”
So, Concors performed the digestive tract surgery in June 2024 and Rizzo performed the lumpectomy a month later.
“Right now, it’s just monitoring,” London says. She has had two CT scans that have shown no evidence of disease, which means regular imaging and checkups going forward — and life with a husband and two girls who were always on her mind throughout the ordeal.
“I remember going down that dark road, and I know those feelings are normal,” she says. “But it’s also important to surround yourself with the right team, and to know that it can be OK — you can be OK, but you’ll go through a lot of stuff. Yes, there is a before and an after. But that doesn’t mean you can’t live a very happy and fulfilled life.”
Jerry Grillo is a veteran journalist and two-time Georgia Author of the Year nominee.
Designed by Linda Dobson
Photography by Jenni Girtman
Care tailored to your needs
Care for patients with cancer at Winship includes leading cancer specialists collaborating across disciplines to tailor treatment plans to each patient’s needs; innovative therapies and clinical trials; comprehensive patient and family support services; and a care experience aimed at easing the burden of cancer.

